{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:48:33Z","timestamp":1790812113932,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.bpg.2006.11.001","type":"journal-article","created":{"date-parts":[[2007,3,22]],"date-time":"2007-03-22T07:00:49Z","timestamp":1174546849000},"page":"315-324","source":"Crossref","is-referenced-by-count":68,"title":["Treatment of Helicobacter pylori"],"prefix":"10.1016","volume":"21","author":[{"given":"K.","family":"Wolle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Malfertheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.bpg.2006.11.001_bib1","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.3748\/wjg.v12.i15.2398","article-title":"Does Helicobacter pylori infection eradication modify peptic ulcer prevalence? A 10 years endoscopical survey","volume":"12","author":"Nervi","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bpg.2006.11.001_bib2","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1111\/j.1572-0241.2004.40014.x","article-title":"Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis","volume":"99","author":"Ford","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2006.11.001_bib3","unstructured":"Malfertheiner P, Megraud F, O'Morain C et\u00a0al. Current concepts in the management of Helicobacter pylori infection-The Maastricht III Consensus Report. GUT online Dec 14, 2006."},{"key":"10.1016\/j.bpg.2006.11.001_bib4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1365-2036.2005.02418.x","article-title":"Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?","volume":"21","author":"Gisbert","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11908-005-0071-4","article-title":"Update on therapeutic options for Helicobacter pylori-related diseases","volume":"7","author":"Megraud","year":"2005","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.bpg.2006.11.001_bib6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1572-0241.2006.00454.x","article-title":"Helicobacter pylori treatment: a practical approach","volume":"101","author":"Vakil","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2006.11.001_bib7","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/j.1572-0241.2005.50019.x","article-title":"Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomised trial","volume":"100","author":"Calvet","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2006.11.001_bib8","first-page":"1935","article-title":"Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment?","volume":"100","author":"Gisbert","year":"2005","journal-title":"Am\u00a0J\u00a0Gastroenterol"},{"key":"10.1016\/j.bpg.2006.11.001_bib9","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1046\/j.1365-2036.2003.01566.x","article-title":"Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis","volume":"17","author":"Gene","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.0083-8703.2006.00370.x","article-title":"Twice-a-day quadruple therapy for eradication of Helicobacter pylori in the elderly","volume":"11","author":"Dore","year":"2006","journal-title":"Helicobacter"},{"key":"10.1016\/j.bpg.2006.11.001_bib11","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1365-2036.2004.02248.x","article-title":"Meta- analysis: the efficacy, adverse events, and adherence related to first-line ant-Helicobacter pylori quadruple therapies","volume":"20","author":"Fischbach","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib12","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1365-2036.2002.01276.x","article-title":"Review article: Helicobacter pylori rescue regimen when proton pump inhibitor- based triple therapies fail","volume":"16","author":"Gisbert","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1046\/j.1365-2036.2003.01759.x","article-title":"Second-line treatment for failure to eradicate Helicobacter pylori: a randomised trial comparing four treatment strategies","volume":"18","author":"Lamouliatte","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00535-004-1443-5","article-title":"Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen","volume":"39","author":"Nagahara","year":"2004","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.bpg.2006.11.001_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-2036.2002.01173.x","article-title":"High rate of posttherapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomised study","volume":"16","author":"Peitz","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1365-2036.2000.00761.x","article-title":"Randomised study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens","volume":"14","author":"Michopoulos","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2036.2002.01220.x","article-title":"Effectiveness of two quadruple tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies","volume":"16","author":"Georgopoulos","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1523-5378.1999.99307.x","article-title":"Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump-inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases","volume":"4","author":"Gomoll\u00f3n","year":"1999","journal-title":"Helicobacter"},{"key":"10.1016\/j.bpg.2006.11.001_bib19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1046\/j.1365-2036.1999.00508.x","article-title":"The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori","volume":"13","author":"Pilotto","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib20","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1046\/j.1365-2036.2003.01541.x","article-title":"Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?","volume":"17","author":"Miwa","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1523-5378.2003.00158.x","article-title":"A prospective, randomised study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin","volume":"8","author":"Miehlke","year":"2003","journal-title":"Helicobacter"},{"key":"10.1016\/j.bpg.2006.11.001_bib22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1365-2036.2004.01910.x","article-title":"High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection","volume":"19","author":"Cammarota","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1523-5378.2003.00128.x","article-title":"Rescue therapy with rifabutin after multiple Helicobacter pylori treatment failures","volume":"8","author":"Gisbert","year":"2003","journal-title":"Helicobacter"},{"key":"10.1016\/j.bpg.2006.11.001_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2036.2006.02793.x","article-title":"Efficacy and safety of rifabutin-containing rescue therapy for resistant Helicobacter pylori infection","volume":"23","author":"Borody","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2036.2005.02522.x","article-title":"A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses","volume":"22","author":"Gatta","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2036.2006.02756.x","article-title":"A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication","volume":"23","author":"Giannini","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2036.2006.02764.x","article-title":"Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection","volume":"23","author":"Wong","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-5378.2002.00087.x","article-title":"Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures","volume":"7","author":"Treiber","year":"2002","journal-title":"Helicobacter"},{"key":"10.1016\/j.bpg.2006.11.001_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2036.2004.02210.x","article-title":"Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients","volume":"21","author":"Qasim","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib30","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2036.2005.02370.x","article-title":"New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study","volume":"21","author":"Coelho","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1572-0241.2006.00457.x","article-title":"Third line rescue therapy with levofloxacin after two H.\u00a0pylori treatment failures","volume":"101","author":"Gisbert","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2006.11.001_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2036.2006.02737.x","article-title":"Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure","volume":"23","author":"Gisbert","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib33","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1572-0241.2006.00637.x","article-title":"Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis","volume":"101","author":"Saad","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2006.11.001_bib34","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/jac\/46.6.1029","article-title":"Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990\u20131999)","volume":"46","author":"Cabrita","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bpg.2006.11.001_bib35","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/AAC.47.12.3942-3944.2003","article-title":"Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori","volume":"47","author":"Tankovic","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bpg.2006.11.001_bib36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1083-4389.2004.00220.x","article-title":"Efficacy of two rabeprazole\/gatifloxacin-based triple therapies for Helicobacter pylori infection","volume":"9","author":"Shahara","year":"2004","journal-title":"Helicobacter"},{"key":"10.1016\/j.bpg.2006.11.001_bib37","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1365-2036.2005.02412.x","article-title":"Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection","volume":"21","author":"Nista","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.0083-8703.2006.00371.x","article-title":"Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection","volume":"11","author":"Cheon","year":"2006","journal-title":"Helicobacter"},{"key":"10.1016\/j.bpg.2006.11.001_bib39","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1128\/AAC.44.4.1075-1077.2000","article-title":"Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis","volume":"44","author":"Heep","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bpg.2006.11.001_bib40","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1046\/j.1440-1746.2003.03058.x","article-title":"Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori","volume":"18","author":"Roghani","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2006.11.001_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1155\/2003\/241508","article-title":"What constitutes failure of H. pylori eradication therapy?","volume":"17","author":"Malfertheiner","year":"2003","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.bpg.2006.11.001_bib42","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1046\/j.1365-2036.2003.01592.x","article-title":"Review article: the treatment of refractory Helicobacter pylori infection","volume":"17","author":"Megraud","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib43","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/gut.2003.022111","article-title":"H pylori antibiotic resistance prevalence, importance, and advances in testing","volume":"53","author":"Megraud","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2006.11.001_bib44","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(00)04972-2","article-title":"Variation in antibiotic use in the European Union","volume":"357","author":"Cars","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2006.11.001_bib45","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1365-2036.1999.00555.x","article-title":"A systematic review of Helicobacter pylori eradication therapy\u2014the impact of anti-microbial resistance on eradication rates","volume":"13","author":"Houben","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib46","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1099\/0022-1317-51-8-705","article-title":"Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000","volume":"51","author":"Wolle","year":"2002","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.bpg.2006.11.001_bib47","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1365-2036.2004.01930.x","article-title":"Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population","volume":"19","author":"Koivisto","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib48","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/archinte.161.9.1217","article-title":"Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States","volume":"161","author":"Osato","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.bpg.2006.11.001_bib49","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0002-9270(99)00258-0","article-title":"The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis","volume":"94","author":"van der Wouden","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2006.11.001_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2036.2003.01396.x","article-title":"Risk factors for failure of Helicobacter pylori therapy\u2014results of an individual data analysis of 2751 patients","volume":"17","author":"Broutet","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib51","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/j.1572-0241.2002.07063.x","article-title":"Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study","volume":"97","author":"Cremonini","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2006.11.001_bib52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.0306-5251.2001.01531.x","article-title":"Management of Helicobacter pylori eradication\u2014the influence of structured counselling and follow-up","volume":"53","author":"Al-Aiden","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bpg.2006.11.001_bib53","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1128\/JCM.39.4.1319-1322.2001","article-title":"CagA status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with non-ulcer dyspepsia","volume":"39","author":"Broutet","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bpg.2006.11.001_bib54","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gut.46.3.321","article-title":"Importance of Helicobacter pylori cag-A and vac-A status for the efficacy of antibiotic treatment","volume":"46","author":"van Doorn","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2006.11.001_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/gut.37.1.39","article-title":"Intra-gastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin","volume":"37","author":"Labenz","year":"1995","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2006.11.001_bib56","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1067\/mcp.2001.119721","article-title":"Effect of high-dose lansoprazole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P450 2C19","volume":"70","author":"Furuta","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib57","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1365-2036.2005.02329.x","article-title":"Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication","volume":"21","author":"Janssen","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib58","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S1590-8658(03)00412-2","article-title":"Lactoferrin: milking ulcers?","volume":"35","author":"Borody","year":"2003","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.bpg.2006.11.001_bib59","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1365-2036.2006.02851.x","article-title":"Bovine lactoferrin for Helicobacter pylori eradication: an open, randomised, multi-centre study","volume":"23","author":"Di Mario","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib60","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.dld.2005.01.017","article-title":"Quadruple therapy with lactoferrin for Helicobacter pylori eradication: a randomised, multi-centre study","volume":"37","author":"Zullo","year":"2005","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.bpg.2006.11.001_bib61","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1046\/j.1440-1746.2003.03102.x","article-title":"Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin resistant Helicobacter pylori infection","volume":"18","author":"Ushiyama","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2006.11.001_bib62","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1083-4389.2004.00214.x","article-title":"The influence of Lactobacillus brevis on ornithine decarboxylase activity and polyamine profiles in Helicobacter pylori-infected gastric mucosa","volume":"9","author":"Linsalata","year":"2004","journal-title":"Helicobacter"},{"key":"10.1016\/j.bpg.2006.11.001_bib63","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1083-4389.2004.00264.x","article-title":"Selective and effective bactericidal activity of the cobalt (II) cation against Helicobacter pylori","volume":"9","author":"Bruggraber","year":"2004","journal-title":"Helicobacter"},{"key":"10.1016\/j.bpg.2006.11.001_bib64","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1523-5378.2003.00175.x","article-title":"Inhibition of Helicobacter pylori induced nuclear factor-kappa B activation and interleukin-8 gene expression by ecabet sodium in gastric epithelial cells","volume":"8","author":"Kim","year":"2003","journal-title":"Helicobacter"},{"key":"10.1016\/j.bpg.2006.11.001_bib65","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1046\/j.1365-2036.18.s1.5.x","article-title":"Review article: the role of rebamipide in the management of inflammatory disease of the gastrointestinal tract","volume":"18","author":"Genta","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2006.11.001_bib66","doi-asserted-by":"crossref","first-page":"7499","DOI":"10.3748\/wjg.v11.i47.7499","article-title":"Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori","volume":"11","author":"O'Mahony","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bpg.2006.11.001_bib67","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1099\/jmm.0.45880-0","article-title":"Activity of Bulgarian propolis against 94 Helicobacter pylori strains in vitro by agar-well diffusion, agar dilution and disc diffusion methods","volume":"54","author":"Boyanova","year":"2005","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.bpg.2006.11.001_bib68","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.diagmicrobio.2004.08.011","article-title":"Susceptibility of Helicobacter pylori isolates to the anti-adhesion activity of a high-molecular-weight constituent of cranberry","volume":"50","author":"Shmuely","year":"2004","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691806001387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691806001387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T12:53:44Z","timestamp":1546952024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691806001387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S1521691806001387"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2006.11.001","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}